Biotech News

BioMarin to Attend Three Upcoming Investor Conferences

BioMarin Pharmaceutical (BMRN)BioMarin PharmaceuticalConference / presentation

- Credit Suisse 25 th Annual Healthcare Conference on November 7 in Scottsdale, Arizona

- Jefferies 2016 London Healthcare Conference on November 16 in London

- Citi 2016 Global Healthcare Conference on December 8 in New York City

SAN RAFAEL, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will participate in the Credit Suisse 25 th Annual Healthcare Conference on November 7, 2016 at 10:00am MT/12:00pm ET, in Scottsdale, Arizona. Management will also participate in the Jefferies 2016 London Healthcare Conference on November 16, 2016, in London and the Citi 2016 Global Healthcare Conference on December 8, 2016 at 8:45am ET, in New York City. Webcasts will be available for the Credit Suisse and Citi conferences. To access the live webcasts, please visit the investor section of the BioMarin website, www.BMRN.com . A replay will also be archived on the site for at least one week following the event.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.

For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press release.

Related news

BioMarin Pharmaceutical

BioMarin is a rare-disease biotechnology company with a portfolio built around enzyme therapies, rare disease commercialization, and pipeline expansion. It remains one of the clearest pure-play rare-disease names in public biotech.

Recent company news

Stock data

Close
61.46 USD
Market cap
10.31B USD
Exchange
NASDAQ
Sector
Gene Therapy
Location
United States